peopl
republ
china
commonli
known
china
compris
approxim
onefifth
world
popul
expand
size
densiti
popul
frequent
interact
peopl
anim
china
hotspot
emerg
spread
new
microbi
threat
major
contributor
worldwid
infecti
diseas
burden
recent
year
emerg
rapid
spread
sever
acut
respiratori
syndrom
sar
gener
consider
interest
chines
healthcar
system
infect
control
prevent
measur
review
examin
antibiot
misus
statu
antibiot
resist
chines
healthcar
system
china
high
rate
antibiot
resist
driven
misus
agent
healthcar
system
provid
strong
incent
overprescrib
countri
selfmed
common
tuberculosi
remain
seriou
problem
china
high
preval
multidrugresist
extens
drugresist
strain
drug
resist
amongst
nosocomi
bacteria
rapid
upward
trend
strong
inclin
toward
multidrug
resist
need
effect
infect
prevent
control
measur
strict
use
antibiot
china
control
rise
spread
antibiot
resist
countri
peopl
republ
china
commonli
known
china
largest
countri
east
asia
popul
world
billion
peopl
approxim
onefifth
world
popul
sinc
establish
china
seen
increas
life
expect
coupl
decreas
infant
mortal
signific
reduct
rate
infecti
diseas
thought
major
contribut
factor
howev
expand
size
densiti
popul
increas
econom
migrat
frequent
interact
peopl
anim
china
major
contributor
worldwid
infecti
diseas
burden
hotspot
spread
infecti
diseas
emerg
new
microbi
threat
eg
emerg
rapid
spread
sever
acut
respiratori
syndrom
sar
china
throughout
world
chines
healthcar
system
henc
becom
focu
world
attent
despit
chines
govern
effort
improv
healthcar
system
still
face
number
challeng
includ
high
cost
restrict
access
health
servic
increas
drug
resist
amongst
pathogen
high
rate
nosocomi
infect
driven
poorli
train
public
health
workforc
insuffici
understand
role
diseas
control
rel
studi
investig
antibiot
resist
antibiot
misus
china
review
examin
statu
antibiot
resist
chines
healthcar
system
misus
agent
countri
search
perform
pubm
decemb
use
combin
search
term
china
antibiot
resist
nosocomi
infect
surveil
refer
relev
articl
also
handsearch
articl
also
select
relev
peerreview
chines
journal
local
nation
antimicrobi
surveil
report
publish
decid
focu
search
last
decad
order
review
current
recent
trend
drug
resist
amongst
healthcareassoci
pathogen
countri
widespread
use
misus
antibiot
worldwid
led
emerg
drugresist
bacteria
coupl
increas
risk
side
effect
increas
treatment
cost
problem
particularli
acut
china
antibiot
prescrib
practic
strong
incent
overprescrib
overthecount
avail
antibiot
consequ
china
high
rate
antibiot
resist
antibiot
use
incorrectli
suscept
bacteri
infect
also
frequent
problem
known
bacteri
aetiolog
one
report
guizhou
provinc
southern
china
cough
diarrhoea
almost
univers
treat
antibiot
whilst
cold
normal
treat
antivir
antibiot
moreov
although
antibiot
resist
known
physician
mani
patient
well
understood
often
view
properti
acquir
patient
microorgan
anoth
studi
patient
outpati
depart
beij
children
hospit
diagnos
common
cold
given
antibiot
patient
take
antibiot
come
hospit
econom
factor
also
influenc
antibiot
prescrib
china
heath
system
strong
financi
incent
drug
prescript
includ
physician
profitsplit
pharmaceut
supplier
fact
drug
sale
profit
form
major
part
chines
hospit
incom
dong
et
al
investig
antibiot
prescrib
pattern
villag
health
clinic
counti
provinc
western
china
percentag
prescript
antibiot
high
provinc
higher
figur
alreadi
report
china
figur
much
higher
develop
countri
usa
spain
northern
europ
dong
et
al
found
prescript
one
antibiot
compris
prescript
wherea
two
antibiot
two
antibiot
repres
respect
prescript
number
antibiot
per
prescript
reach
nearli
provinc
moreov
selfmed
taken
consider
studi
true
frequenc
proport
antibiot
use
may
underestim
anoth
studi
wu
et
al
investig
antibiot
use
chines
hospit
day
august
inpati
investig
use
antibiot
antibiot
use
therapeut
purpos
whilst
prophylaxi
therapi
prophylaxi
microbiolog
investig
antibiot
prescript
rare
done
amongst
patient
therapeut
antibiot
sampl
sent
pathogen
detect
inappropri
antibiot
use
add
grow
antimicrobi
resist
countri
also
add
inpati
cost
yang
et
al
investig
antibiot
use
amongst
case
antibiot
treatment
hospit
five
chines
provinc
report
rate
antibiot
misus
ad
unnecessari
cost
inpati
drug
resist
china
common
sexual
transmit
diseas
includ
hivaid
howev
resist
amongst
nosocomi
bacteria
rapid
upward
trend
countri
one
studi
compar
pattern
antibiot
resist
amongst
bacteria
clinic
relev
china
kuwait
usa
report
china
highest
level
antibiot
resist
rapid
growth
rate
resist
amongst
three
countri
averag
increas
year
compar
growth
record
usa
past
two
decad
increas
number
multidrugresist
tuberculosi
mdrtb
case
around
world
mdrtb
defin
strain
tuberculosi
combin
resist
isoniazid
rifampicin
report
world
health
organ
rank
china
one
world
largest
number
tb
case
high
level
mdrtb
base
recent
nation
estim
new
mdrtb
case
diagnos
annual
china
account
ca
global
burden
mdrtb
one
studi
reveal
mean
preval
drug
resist
amongst
new
tb
case
chines
provinc
high
place
amongst
previous
treat
case
mean
increas
provinc
surveil
preval
mdrtb
shanghai
pulmonari
tb
patient
survey
resist
firstlin
antitb
drug
mdrtb
studi
show
much
higher
level
mdrtb
countri
mean
amongst
case
amongst
new
case
amongst
previous
treat
case
report
emerg
spread
extens
drugresist
xdr
tb
china
particularli
problemat
difficult
expens
treat
high
mortal
rate
xdrtb
defin
mdrtb
strain
resist
fluoroquinolon
least
one
three
inject
secondlin
drug
includ
amikacin
kanamycin
capreomycin
sun
et
al
characteris
first
xdrtb
china
clinic
tuberculosi
isol
collect
hivneg
tb
patient
beij
chest
hospit
also
report
isol
collect
mdrtb
xdrtb
wang
et
al
found
higher
rate
mdrtb
xdrtb
amongst
tuberculosi
strain
isol
patient
beij
hospit
amongst
strain
investig
mdrtb
xdrtb
recent
preval
xdrtb
amongst
mdrtb
tuberculosi
second
largest
provinc
china
shandong
report
tb
situat
china
need
particular
attent
measur
taken
improv
strategi
prevent
control
tb
transmiss
countri
includ
strengthen
exist
tb
infect
control
practic
improv
antibiot
stewardship
screen
latent
tb
infect
latter
particularli
import
amongst
healthcar
worker
hcw
risk
tb
transmiss
patient
may
high
preval
latent
tb
becom
sourc
activ
infect
et
al
found
preval
latent
tb
infect
amongst
hcw
without
bacillu
bcg
vaccin
tb
centr
henan
provinc
china
respect
case
pulmonari
tb
detect
amongst
hcw
gramneg
bacteria
amongst
commonli
isol
pathogen
nosocomi
infect
china
studi
surveil
data
report
increas
antimicrobi
resist
amongst
gramneg
especi
amongst
nonfer
pathogen
pseudomona
acinetobact
spp
countri
tendenc
toward
multidrug
resist
emerg
carbapenem
resist
panresist
enterobacteriacea
pseudomona
acinetobact
spp
drug
resist
differ
speci
gramneg
bacilli
isol
chines
hospit
investig
li
et
al
isol
hospitalacquir
infect
hai
communityacquir
infect
cai
hai
isol
resist
antimicrobi
agent
cai
especi
enterobact
cloaca
serratia
spp
acinetobact
spp
resist
pseudomona
aeruginosa
fluoroquinolon
increas
escherichia
coli
strain
found
resist
agent
anoth
studi
conclud
antibiot
resist
rate
bacteria
investig
chines
intens
care
unit
icu
rise
gradual
strong
inclin
toward
multidrug
resist
gramneg
bacilli
mostli
p
aeruginosa
e
coli
could
resist
four
antibiot
rate
resist
exceed
amongst
gramneg
member
enterobacteriacea
famili
frequent
associ
nosocomi
infect
chines
hospit
organ
may
express
extendedspectrum
esbl
confer
resist
resist
also
commonli
associ
resist
aminoglycosid
sulfonamid
fluoroquinolon
recent
carbapenem
treatment
choic
seriou
infect
due
esblproduc
howev
carbapenem
resist
emerg
enterobacteriacea
famili
variou
mechan
major
concern
worldwid
china
nosocomi
pathogen
resist
surveil
studi
group
conduct
comprehens
studi
investig
antimicrobi
resist
amongst
gramneg
clinic
isol
icu
patient
hospit
studi
period
decreas
rate
suscept
cephalosporin
ciprofloxacin
cefoperazonesulbactam
observ
particularli
amongst
e
coli
ciprofloxacin
cefotaxim
amongst
enterobact
spp
ceftazidim
cefotaxim
anoth
bacteri
resist
surveil
studi
hospit
china
reveal
e
coli
klebsiella
spp
strain
resist
firstand
secondgener
cephalosporin
compound
resist
rate
thirdgener
cephalosporin
exclud
ceftazidim
rang
escherichia
coli
strain
particularli
highli
resist
fluoroquinolon
ca
strain
resist
drug
yang
et
al
report
antimicrobi
resist
amongst
enterobacteriacea
isol
patient
intraabdomin
infect
iai
china
found
suscept
rate
test
thirdand
fourthgener
cephalosporin
declin
nearli
increas
resist
fluoroquinolon
e
coli
also
note
suscept
ciprofloxacin
decreas
esblproduc
show
higher
antimicrobi
resist
compar
nonesblproduc
report
investig
recent
chines
nation
drug
resist
surveil
report
found
preval
esblproduc
amongst
e
coli
klebsiella
respect
rate
accord
report
chines
investig
tabl
onehalf
esblproduc
resist
ciprofloxacin
gentamicin
e
coli
strain
panresist
yang
et
al
found
carbapenem
activ
enterobacteriacea
suscept
rate
agent
test
howev
carbapenemnonsuscept
detect
small
percentag
isol
isol
nonsuscept
imipenem
ertapenem
respect
similar
carbapenem
resist
found
amongst
enterobacteriacea
isol
recent
chines
nation
drug
resist
surveil
report
howev
notic
increas
number
resist
isol
compar
data
note
particularli
amongst
k
pneumonia
klebsiella
pneumonia
carbapenemas
kpc
produc
panresist
strain
emerg
china
wide
report
variou
region
peopl
republ
pseudomona
aeruginosa
anoth
common
pathogen
chines
hospit
organ
uniqu
problemat
nosocomi
pathogen
natur
resist
mani
drug
famili
abil
acquir
rapidli
develop
resist
multipl
class
antibiot
cours
treat
patient
data
china
suggest
past
decad
antibiot
resist
amongst
p
aeruginosa
clinic
isol
increas
especi
carbapenem
investig
chang
antimicrobi
resist
amongst
nonfer
gramneg
bacilli
isol
chines
icu
found
p
aeruginosa
predomin
pathogen
isol
organ
becom
less
suscept
antibiot
studi
period
anoth
studi
p
aeruginosa
isol
icu
patient
chines
hospit
report
mark
decreas
p
aeruginosa
suscept
imipenem
recent
report
howev
show
stabl
high
carbapenem
resist
rate
tabl
tendenc
toward
multidrug
resist
studi
p
aeruginosa
isol
iai
found
ca
isol
resist
imipenem
meropenem
respect
similar
resist
rate
report
number
recent
chines
antimicrobi
resist
surveil
public
percentag
p
aeruginosa
mdr
strain
defin
isol
resist
three
four
antimicrobi
amongst
ceftazidim
ciprofloxacin
amikacin
imipenem
report
increas
period
recent
nation
surveil
studi
found
p
aeruginosa
isol
collect
hospit
china
mdr
panresist
found
p
aeruginosa
isol
test
recent
chines
nation
survey
amikacin
remain
one
activ
agent
p
aeruginosa
china
isol
suscept
drug
acinetobact
baumannii
recent
gain
increas
notorieti
nosocomi
pathogen
one
preval
gramneg
bacteria
isol
chines
hospit
particularli
icu
acinetobact
seriou
pathogen
chines
hospit
especi
emerg
spread
problemat
strain
new
delhi
carbapenemaseproduc
isol
well
high
preval
xdr
panresist
strain
countri
zhang
et
al
report
recent
statu
antimicrobi
resist
amongst
clinic
isol
baumannii
china
found
amongst
antibiot
test
cefoperazonesulbactam
minocyclin
activ
resist
rate
ca
antimicrobi
resist
agent
higher
especi
amongst
icu
isol
multidrug
resist
panresist
note
isol
respect
imipenem
meropenem
resist
rate
respect
rate
higher
report
earlier
nation
survey
line
gradual
increas
year
carbapenem
resist
china
imipenem
meropenem
resist
acinetobact
seen
sharp
increas
china
recent
year
gramposit
bacteria
particularli
gramposit
cocci
genera
staphylococcu
enterococcu
streptococcu
contain
import
pathogen
speci
caus
seriou
infect
associ
morbid
mortal
speci
commonli
isol
nosocomi
infect
hospit
across
china
staphylococcu
aureu
major
pathogen
associ
infect
hospit
commun
set
infect
caus
meticillinsensit
aureu
howev
meticillinresist
aureu
mrsa
implic
seriou
infect
outbreak
preval
mrsa
amongst
aureu
clinic
isol
increas
sharpli
china
last
year
tabl
rate
high
report
chines
surgic
icu
data
shanghai
show
preval
mrsa
increas
reach
li
et
al
investig
bacteri
resist
hai
cai
china
report
preval
mrsa
aureu
isol
significantli
higher
patient
hai
patient
cai
subsequ
studi
mrsa
account
aureu
isol
rate
hai
patient
also
significantli
higher
cai
patient
preval
meticillin
resist
even
higher
amongst
coagulaseneg
staphylococci
con
tabl
chen
et
al
report
meticillinresist
con
repres
nosocomi
infect
chines
surgic
icu
meticillin
resist
present
con
isol
comprehens
report
bacteri
resist
china
investig
clinic
bacteri
isol
collect
chines
hospit
found
aureu
isol
meticillinresist
resist
rate
fluoroquinolon
macrolid
high
isol
respect
con
show
higher
resist
strain
meticillinresist
fluoroquinolon
macrolid
resist
rate
compar
aureu
streptococcu
pneumonia
remain
import
pathogen
caus
signific
morbid
mortal
especi
amongst
young
children
emerg
spread
penicillinresist
mdr
strain
around
world
great
concern
avail
data
china
tabl
show
past
year
rate
penicillin
macrolid
resist
pneumonia
increas
significantli
especi
amongst
paediatr
popul
rate
penicillinnonsuscept
resist
intermedi
resist
pneumonia
increas
amongst
paediatr
popul
rate
doubl
increas
pneumonia
resist
penicillin
china
mirror
increas
multidrug
resist
especi
macrolid
resist
macrolid
particularli
problemat
agent
firstchoic
treatment
pneumonia
surveil
studi
beij
resist
erythromycin
clarithromycin
tetracyclin
seen
pneumonia
isol
respect
xiao
et
al
found
pneumonia
clinic
isol
resist
macrolid
clindamycin
recent
studi
yao
et
al
report
pneumonia
strain
isol
chines
children
pneumonia
penicillinnonsuscept
penicillinresist
almost
isol
resist
erythromycin
multidrug
resist
especi
common
amongst
penicillinresist
pneumonia
strain
one
studi
report
mdr
enterococcu
commonli
isol
organ
chines
hospit
enterococcu
faecali
enterococcu
faecium
account
infect
caus
genu
vancomycin
resist
one
disturb
drug
resist
trend
emerg
within
speci
vancomycinresist
enterococci
vre
seriou
nosocomi
pathogen
infect
due
vre
associ
signific
morbid
mortal
well
increas
hospit
cost
vre
infect
colonis
first
report
franc
uk
throughout
world
china
surveil
data
bacteri
resist
clinic
isol
shanghai
hospit
report
vancomycinresist
e
faecali
e
faecium
frequenc
icu
intens
care
unit
respect
howev
vre
concern
mainland
china
june
first
nosocomi
infect
recognis
beij
chaoyang
hospit
sinc
vre
report
number
chines
studi
total
clinic
isol
collect
beij
chaoyang
hospit
confirm
vre
correl
vancomycin
usag
misus
vre
incid
observ
worryingli
coexist
mrsa
vre
patient
report
case
suggest
coexist
rare
occurr
recent
local
nation
report
tabl
suggest
vre
preval
china
remain
low
howev
rate
increas
china
major
contributor
worldwid
infecti
diseas
burden
hotspot
emerg
spread
new
microbi
threat
sar
epidem
brought
world
attent
emerg
infecti
diseas
control
countri
china
high
rate
antibiot
resist
driven
misus
antimicrobi
agent
commun
healthcar
system
provid
strong
incent
overprescrib
true
frequenc
proport
antibiot
use
may
underestim
especi
rural
area
overthecount
antibiot
selfmed
common
drug
resist
amongst
nosocomi
bacteria
rapid
upward
trend
china
strong
inclin
toward
multidrug
resist
hospit
strain
show
resist
antibiot
like
mdr
nonhospit
strain
mdrtb
rate
high
increas
emerg
spread
xdrtb
countri
particularli
problemat
difficult
expens
treat
high
mortal
rate
larg
proport
gramneg
nosocomi
strain
isol
china
resist
antibiot
nonferment
highli
resist
preval
esblproduc
amongst
enterobacteriacea
high
strain
show
higher
antimicrobi
resist
compar
nonesblproduc
also
worri
evid
emerg
increas
preval
carbapenem
resist
panresist
enterobacteriacea
pseudomona
acinetobact
spp
china
preval
mrsa
amongst
aureu
clinic
isol
increas
sharpli
china
rate
high
report
preval
mrsa
significantli
higher
isol
patient
hai
patient
cai
past
year
resist
rate
penicillin
macrolid
amongst
pneumonia
isol
also
increas
significantli
especi
amongst
chines
paediatr
popul
vre
becam
real
concern
china
sinc
june
first
vre
nosocomi
infect
recognis
increas
rate
vre
coexist
mrsa
vre
patient
particularli
troubl
despit
chines
govern
effort
improv
healthcar
system
peopl
republ
still
face
number
challeng
need
effect
infect
prevent
control
measur
stricter
use
antibiot
china
control
rise
antibiot
resist
countri
fund
fund
sourc
compet
interest
sy
employ
bioquel
uk
ltd
andov
uk
hl
compet
interest
declar
ethic
approv
requir
